Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the following criteria:~  * Histologically confirmed NSGCT~ * Clinical evidence of disease AND high serum human chorionic gonadotropin (HCG) or alpha-fetoprotein (AFP) levels~* Clinical stage II-III disease (disseminated disease)~* Testicular, retroperitoneal, or mediastinal primary site~* Poor prognosis disease, meeting 1 of the following criteria:~  * Mediastinal primary site~ * Non-pulmonary visceral metastases~ * One of the following lab values:~    * HCG \> 50,000 UI/L~   * AFP \> 10,000 ng/mL~   * Lactate dehydrogenase \> 10 times upper limit of normal (ULN)~PATIENT CHARACTERISTICS:~Age~* Over 16~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 times ULN~Renal~* Creatinine clearance \> 60 mL/min~Other~* No other prior malignancy except basal cell skin cancer~* No HIV positivity~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
- Arm II (Type: EXPERIMENTAL): Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.

Based on this trial design, predict the completion outcome and termination type (if applicable).